Categoria
Quibron T/SR
Nombres de marca,
Quibron T/SR
Analogos
Quibron T/SR
Marca los nombres de mezcla
Bronchyl Syrup (alcohol anhydrous + beechwood creosote + cocillana + eucalyptus + guaiacol oleate + ipecac + lobelia inflata + menthol + myroxylon balsamum + theophylline + white pine) Choledyl Expectorant Elixir (guaifenesin + oxtriphylline) Diuerb tab (oil of fleabane + theophylline + urea) IDM Expectorant tab (guaifenesin + potassium iodide + pyrilamine maleate + theophylline) IDM tab (potassium iodide + pyrilamine maleate + theophylline) PMS-Oxtriphylline Elixir (alcohol anhydrous + oxtriphylline) Pulmo Septol Sirop (beechwood creosote + cocillana + eucalyptus oil + guaiacol + ipecac + lobelia inflata + myroxylon balsamum + theophylline + white pine) Ratio-theo-bronc (guaifenesin + potassium iodide + pyrilamine maleate + theophylline) Tedral tab (l-ephedrine hydrochloride + phenobarbital + theophylline) Theophylline 0.8mg and 5% dextrose inj (dextrose + theophylline) Theophylline 0.8mg/ml in 5% dextrose inj (dextrose + theophylline) Theophylline 1.6mg and 5% dextrose inj (dextrose + theophylline) Theophylline 4mg and 5% dextrose inj (dextrose + theophylline) Theophylline rougier elixir (alcohol anhydrous + theophylline)
Quibron T/SR
Formula quimica
C7H8N4O2
Quibron T/SR
RX enlace
http://www.rxlist.com/cgi/generic/theosr.htm
Quibron T/SR
FDA hoja
Quibron T/SR
MSDS (hoja de seguridad de materiales)
Quibron T/SR
Sintesis de referencia
Traube, Ber. 33, (1940)
Quibron T/SR
Peso molecular
180.164 g/mol
Quibron T/SR
Punto de fusion
272 oC
Quibron T/SR
H2O Solubilidad
1.5 g / L
Quibron T/SR
Estado
Solid
Quibron T/SR
LogP
-0.773
Quibron T/SR
Formas de dosificacion
Cápsulas (liberación sostenida), Elixir, líquido, Tablet, Tablet (de liberación prolongada)
Quibron T/SR
Indicacion
Para el tratamiento de los síntomas y la obstrucción reversible al flujo aéreo asociada con el asma crónica y otras enfermedades pulmonares crónicas, tales como enfisema y bronquitis crónica.
Quibron T/SR
Farmacologia
Teofilina, un derivado de la xantina químicamente similar a la cafeína y la teobromina, se utiliza para tratar el asma y broncoespasmos. La teofilina tiene dos acciones distintas en las vías respiratorias de los pacientes con reversible (Asmáticos) la obstrucción, la relajación del músculo liso (es decir, la broncodilatación) y la supresión de la respuesta de las vías respiratorias a los estímulos (es decir, no broncodilatadora efectos profilácticos).
Quibron T/SR
Absorcion
La teofilina se absorbe rápida y completamente tras la administración oral en solución o de liberación inmediata de forma sólida de dosificación oral.
Quibron T/SR
Toxicidad
Los síntomas de sobredosis incluyen convulsiones, arritmias, y los efectos gastrointestinales.
Quibron T/SR
Informacion de Pacientes
Immediate Release Products
The patient (or parent/care giver) should be instructed to seek medical advice whenever nausea, vomiting,
persistent headache, insomnia or rapid heart beat occurs during treatment with theophylline, even if another cause is
suspected. The patient should be instructed to contact their clinician if they develop a new illness, especially if
accompanied by a persistent fever, if they experience worsening of a chronic illness, if they start or stop smoking
cigarettes or marijuana, or if another clinician and a new medication or discontinues a previously prescribed
medication. Patients should be instructed to inform all clinicians involved in their care that they are taking
theophylline, especially when a medication is being added or deleted from their treatment. Patients should be
instructed to not alter the dose, timing of the dose, or frequency of administration without first consulting their
clinician. If a dose is missed, the patient should be instructed to take the next dose at the usually scheduled time
and to not attempt to make up for the missed dose.
Extended-Release Capsules
This information is intended to aid in the safe and effective use of this medication. It is not a disclosure of
all possible adverse or intended effects.
The physician should reinforce the importance of taking only the prescribed dose and the time interval between
doses. As with any controlled-release theophylline product, the patient should alert the physician of symptoms occur
repeatedly, especially near the end of the dosing interval.
When prescribing administration by the sprinkle method, details of the proper technique should be explained to
patient
Patients should be informed of the need to take this drug in the fasting state, and that drug administration
should be 1 hour before or 2 hours after meals.
Quibron T/SR
Organismos afectados
Humanos y otros mamíferos